uploads///Lupron

Updates on AbbVie’s AndroGel, Lupron, and Kaletra

By

Updated

AndroGel and Lupron revenue trends

In 4Q17, AbbVie’s (ABBV) AndroGel reported revenue of $140 million, compared with $174 million in 4Q16, reflecting a ~20% decline YoY (year-over-year) and a ~5% decline quarter-over-quarter. In fiscal 2017, AndroGel generated revenue of $577 million, marking a ~14.5% decline YoY.

Lupron reported revenue of $224 million in 4Q17 and $219 million in 4Q16, reflecting ~2% growth YoY and ~11% growth quarter-over-quarter. In 2017, Lupron reported revenue of $829 million, reflecting ~1% YoY growth. In 2017, in US and international markets, Lupron generated revenue of $669 million and $160 million, respectively, representing ~1% and 1.4% YoY growth.

Lupron is used to treat endometriosis, fibrosis, and advanced prostate cancer. In the advanced prostate cancer drug market, Lupron’s peers include AstraZeneca’s (AZN) Casodex and Pfizer’s (PFE), Astellas Pharma’s (ALPMY), and Sanofi’s (SNY) Jevtana.

Article continues below advertisement

Kaletra revenue trends

In 4Q17, Kaletra reported revenue of $113 million, reflecting a ~14.3% YoY decline. In 4Q17, in US market and international markets, Kaletra generated revenue of $17 million and $96 million, respectively, reflecting a ~33.7% and ~9.7% decline YoY.

In fiscal 2017, Kaletra generated revenue of $423 million, marking a ~22.9% YoY decline. In 2017, in US and international markets, Kaletra reported revenue of $71 million and $352 million, respectively, reflecting ~38.6% and ~18.8% YoY growth. Kaletra is used for the treatment of HIV-1 infections.

Advertisement

More From Market Realist